Calcipotriene
Duchenne Muscular Dystrophy (DMD)
Vanderbilt University Medical CenterSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Duchenne Muscular Dystrophy (DMD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dyne-251 Dyne Therapeutics | Phase 3 | B |
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
Entr-601-44 Entrada Therapeutics, Inc. | Phase 1/2 | CC |
Semaglutide Vanderbilt University Medical Center | Phase 1/2 | CC |
Entr-601-45 Entrada Therapeutics, Inc. | Phase 1/2 | CC |
View all 18 →
Same molecule, other indications
Calcipotriene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →